Licensing antibodies

Discovering therapeutic antibodies designed by nature

Licensing an antibody from the AIMM pipeline

AIMM has active internal discovery programs in oncology and infectious diseases. When selecting potential candidates, AIMM sets the bar high. All of AIMM’s portfolio antibodies are either best in class or first in class. Antibody candidates are preferably selected from immune cells of individuals with unique attributes for overcoming disease.

The portfolio includes the following antibody programs

  • Acute Myeloid Leukemia
  • Melanoma
  • Human Cytomegalovirus (HCMV)
  • Influenza virus
  • Hepatitis C virus (HCV)
  • Hepatitis B virus (HBV)
  • Respiratory Syncytial Virus (RSV) targeting the G Protein
  • Parecho virus